MoonLake 10-Q: $498.5M Cash to Mid-2028, Q3 Net Loss $79.5M, 85.1M Shares Out
MLTX sits 23% above its 52-week low of $9.46.
Summary
MoonLake's Q3 10-Q shows $498.5 million in cash and securities with runway to mid-2028, a $79.5 million quarterly net loss swollen by a $17.0 million accrued Merck milestone, and 85.1 million shares outstanding after this year's equity raises.
Key Events · Earnings and Guidance · MLTX
-
Q3 Net Loss $79.5M on Milestone Accrual
Net loss was $79.5 million, or $0.93 per share, versus $70.7 million a year ago. R&D of $68.9 million included a $17.0 million accrued regulatory milestone to Merck KGaA tied to expected BLA acceptance.
-
Cash $498.5M, Runway to Mid-2028
Cash, equivalents and short-term marketable debt securities totaled $498.5 million at September 30, down from $537 million at June 30, with management guiding to funding into mid-2028.
-
Share Count Up to 85.1M
Shares outstanding rose to 85,106,685 from 71,373,579 at December 31, 2025, reflecting the June 2026 offering, the 1,500,000-share over-allotment exercise and ATM sales.
-
ATM: $50.3M Sold, $300M Left
Under the Leerink sales agreement, 2,764,178 shares were sold in the nine months at a weighted average of $18.52 for $50.3 million net; the full $300.0 million prospectus supplement remained available at quarter-end.
Analysis · MLTX · Life Sciences
Hard numbers now sit behind this morning's Q3 release. Cash and short-term securities of $498.5 million, down from $537 million at June 30, fund operations into mid-2028, so there is no near-term financing need. The quarter's $79.5 million net loss, however, was inflated by a $17.0 million accrued milestone to Merck KGaA tied to the expected FDA acceptance of the sonelokimab BLA — a one-time step-up rather than a new run-rate. Share count stands at 85,106,685 versus 71,373,579 at year-end, the cumulative cost of the June offering, its over-allotment and $50.3 million of ATM sales at an $18.52 average. Next hard date: the FDA's acceptance decision on the BLA, expected by end-November 2026.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, MLTX was trading at $11.62 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $995.7M. The 52-week trading range was $9.46 to $23.29. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.